QQ客服 官方微博 反馈留言

	Co-delivery of itraconazole and docetaxel by core/shell lipid nanocells for systemic antiangiogenesis and tumor growth inhibition
	Okeke, Chukwunweike I.1,2,3; Eltahan, Ahmed S.1,2,3; Zhang, Tingbin1,2; Chen, Jing1,2; Wang, Yingze4; Xu, Meng-Qi1,2; Liu, Lu1,2,3; Yang, An-Qi1,2; Guo, Weisheng1,2; Liang, Xing-Jie1,2,3
刊名	Journal of biomedical nanotechnology
	2017-11-01
卷号	13期号:11页码:1398-1412
关键词	Antiangiogenesis Itraconazole Docetaxel Core/shell nanocarrier Combinational therapy
ISSN号	1550-7033
DOI	10.1166/jbn.2017.2428
通讯作者	Wang, yingze(yingzewang@126.com) ; Guo, weisheng(tjuguoweisheng@126.com) ; Liang, xing-jie(liangxj@nanoctr.cn)
英文摘要	The combination of antiangiogenesis with chemotherapy has become a promising multi-modal combinational therapy for solid tumor. however, hypoxia-mediated resistance and the subsequent treatment failure associated with antiangiogenesis therapy have limited the maximization of this promising approach. it remains a major challenge to balance the effect of angiogenesis and the accumulation of the cytotoxic drug within the tumor microenvironment. in this study, we report a nanotechnology based drug delivery solution that would improve both the antiangiogenic activity and cytotoxic efficacy of the loaded drugs. we designed core-shell 'lipid nanocells' drug delivery systems (denoted as dtx/itz-lncs), which entrapped the antiangiogenic drug itraconazole (itz) in the outside liposomal shell and encapsulated anticancer drug docetaxel (dtx) in the inner hydrophobic plga core. in vitro evaluations showed that the dual drug loaded dtx/itz-lncs retained the cytotoxic efficacy of the dtx against both the sensitive and multidrug resistant breast cancer cell line mcf-7. dtx/itz-lncs also effectively inhibited the vascular endothelial growth factor (vegf) induced migratory and invasive actions of huvecs and neovascularization of subcutaneously implanted matrigel plugs. the tumor growth of mcf-7 tumor xenograft model was effectively inhibited by the systemic administration of the dtx/itz-lncs. taken together, these results showed that the dtx/itz-lncs provided a drug delivery platform that can optimize the combinatory effects of the antiangiogenic agent with a conventional chemotherapeutic agent.
WOS关键词	METASTATIC BREAST-CANCER ; MULTIDRUG-RESISTANCE ; 1ST-LINE TREATMENT ; BETA-CYCLODEXTRIN ; ANGIOGENESIS ; BEVACIZUMAB ; THERAPY ; DRUGS ; CHEMOTHERAPY ; PACLITAXEL
WOS研究方向	Science & Technology - Other Topics ; Materials Science
WOS类目	Nanoscience & Nanotechnology ; Materials Science, Biomaterials
语种	英语
出版者	AMER SCIENTIFIC PUBLISHERS
WOS记录号	WOS:000419735100005
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2177903
专题	高能物理研究所
通讯作者	Wang, Yingze; Guo, Weisheng; Liang, Xing-Jie
作者单位	1.Chinese Acad Sci, Ctr Excellence Nanosci, Lab Controllable Nanopharmaceut, Beijing 100190, Peoples R China 2.Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 4.Hebei Univ Sci & Technol, Coll Biol Sci & Engn, Shijiazhuang 050018, Hebei, Peoples R China
推荐引用方式 GB/T 7714	Okeke, Chukwunweike I.,Eltahan, Ahmed S.,Zhang, Tingbin,et al. Co-delivery of itraconazole and docetaxel by core/shell lipid nanocells for systemic antiangiogenesis and tumor growth inhibition[J]. Journal of biomedical nanotechnology,2017,13(11):1398-1412.
APA	Okeke, Chukwunweike I..,Eltahan, Ahmed S..,Zhang, Tingbin.,Chen, Jing.,Wang, Yingze.,...&Liang, Xing-Jie.(2017).Co-delivery of itraconazole and docetaxel by core/shell lipid nanocells for systemic antiangiogenesis and tumor growth inhibition.Journal of biomedical nanotechnology,13(11),1398-1412.
MLA	Okeke, Chukwunweike I.,et al."Co-delivery of itraconazole and docetaxel by core/shell lipid nanocells for systemic antiangiogenesis and tumor growth inhibition".Journal of biomedical nanotechnology 13.11(2017):1398-1412.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。